

Date: June 30, 2026

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Notice of the 20th Annual general Meeting (“AGM”)

Dear Sir/Madam

In compliance with Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby enclosing the Notice convening the 20th Annual General Meeting (AGM) of the Company which is scheduled to be held on Wednesday, July 22, 2026, at 03:30 p.m. IST through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”).

Further, the Company has declared a dividend, subject to the approval of the shareholders at the ensuing AGM, and details regarding deduction of tax at source (TDS) on the final dividend for FY 2025–26 are provided in the Notes to the AGM Notice and are also available on the Company’s website at <https://anthembio.com/wp-content/uploads/2026/06/Communication-on-Tax-Deduction-at-Source-on-Dividend.pdf>.

The Notice is also available on the Company’s website at <https://anthembio.com/wp-content/uploads/2026/06/AGM-Notice.pdf>.

Information at glance:

S. No	Particulars	Details
1.	Time and date of AGM	03.30 PM IST, Wednesday, July 22, 2026
2.	Mode	Video conference and other audio-visual means
3.	Link for participation in AGM through VC	https://emeetings.kfintech.com
4.	Cut-off date for e-voting	Friday, July 17, 2026
5.	E-voting start time & date	9:00 AM (IST) on Sunday, July 19, 2026
6.	E-voting end time and date	5:00 PM (IST) on Tuesday, July 21, 2026
7.	Helpline number for e-voting & VC participation	For any assistance or support before or during the AGM, Members may contact the RTA at: Email: einward.ris@kfintech.com Tel No.: 1800 3094 001
8.	Record date for Final dividend for FY 2026	Friday, June 26, 2026
9.	Dividend Payment date	On or before Friday, August 21, 2026

The above intimation is made available on the Company's website at <https://www.anthembio.com/investors/>

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

Date: June 30, 2026

Dear Member,

Invitation to attend the Annual General Meeting on Wednesday, July 22, 2026

You are cordially invited to attend the Twentieth Annual General Meeting of the Company to be held on Wednesday, July 22, 2026 at 03.30 P.M (IST) through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”).

For ease of participation, key details regarding the meeting are as follows:

S. No	Particulars	Details
1.	Link for participation in AGM through VC	https://emeetings.kfintech.com
2.	Link for remote e-voting	https://evoting.kfintech.com/
3.	Cut-off date for e-voting	Friday, July 17, 2026
4.	E-voting start time & date	9:00 AM (IST) on Sunday, July 19, 2026
5.	E-voting end time and date	5:00 PM (IST) on Tuesday, July 21, 2026
6.	Contact details of Registrar and Share Transfer Agent (RTA)	Kfin Technologies Limited Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana, India Telephone No: 1800 3094 001 Email Id: einward.ris@kfintech.com
7.	Helpline number for e-voting & VC participation	For any assistance or support before or during the AGM, Members may contact the RTA at: Email: einward.ris@kfintech.com Tel No.: 1800 3094 001
8.	Scrutinizer Details	CS Pramod S M (Membership No. F7834) or in his absence CS Biswajit Ghosh (Membership No. F8750) Partners of M/s. BMP & Co. LLP, Practicing Company Secretaries Email: info@bmpandco.com
9.	Record date for Final dividend for FY 2026	Friday, June 26, 2026
10.	Dividend Payment date	On or before Friday, August 21, 2026
11.	Company Contact details	Email: investors.abl@anthembio.com Tel: +91 080 6672 4000

The Notice convening the Annual General Meeting is attached herewith.

Yours Truly,

Sd/-

Divya Prasad

Company Secretary & Compliance Officer

Membership No. A41438

Notice

NOTICE IS HEREBY GIVEN THAT THE TWENTIETH ANNUAL GENERAL MEETING OF THE MEMBERS OF ANTHEM BIOSCIENCES LIMITED WILL BE HELD ON WEDNESDAY, JULY 22, 2026 AT 03.30 P.M THROUGH VIDEO CONFERENCE (“VC”) / OTHER AUDIO-VISUAL MEANS (“OAVM”) TO TRANSACT THE FOLLOWING BUSINESSES SET OUT BELOW:

ORDINARY BUSINESS:

1. TO CONSIDER AND ADOPT THE AUDITED FINANCIAL STATEMENTS (INCLUDING AUDITED CONSOLIDATED FINANCIAL STATEMENTS) OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026 AND THE REPORTS OF THE BOARD OF DIRECTORS AND AUDITORS THEREON

*To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:*

“**RESOLVED THAT** pursuant to the provisions of the Companies Act, 2013 read with the rules made thereunder, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable accounting standards, and as recommended by the Audit Committee and the Board of Directors of the Company, the audited financial statements (including consolidated financial statements) of the Company for the financial year ended March 31, 2026 including the balance sheet, profit and loss account, the cash flow statement for the year ended on that date, reports of auditors and the Board of Directors thereon, be and are hereby received, considered and adopted.”

2. TO DECLARE DIVIDEND

*To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:*

“**RESOLVED THAT** pursuant to Section 123 of the Companies Act, 2013, read with relevant rules and Regulation 43 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Dividend Distribution Policy of the Company and as recommended by the Board of Directors, a final dividend at the rate of ₹ 2.00 (Indian Rupees Two Only) per equity share having a face value of ₹ 2.00 (Indian Rupees Two Only) each, be and is hereby declared for the financial year ended March 31, 2026, and that the same be paid to those Members whose names appear in the Register of Beneficial Owners maintained by the Depositories as on the record date i.e. Friday, June 26, 2026.”

3. TO CONSIDER AND APPROVE THE APPOINTMENT OF MR. K RAVINDRA CHANDRAPPA (DIN: 01580534), WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT

*To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:*

“**RESOLVED THAT** pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013 and as recommended by the Nomination and Remuneration Committee and the Board of Directors, the approval of Members

of the Company, be and is hereby accorded to re-appoint K Ravindra Chandrappa (DIN: 01580534) as a Director, who is liable to retire by rotation.”

4. TO APPOINT M/S. S.R. BATLIBOI & ASSOCIATES LLP, CHARTERED ACCOUNTANTS, (FRN 101049W/E300004) AS THE STATUTORY AUDITORS OF THE COMPANY

*To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:*

“**RESOLVED THAT** pursuant to the provisions of Sections 139, 141, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, and pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory modification(s), amendment(s), clarification(s), re-enactment(s) or substitution(s) thereof for the time being in force, and based on the recommendation of the Audit Committee and the Board of Directors, the consent of the Members be and is hereby accorded to appoint M/s. S.R. Batliboi & Associates LLP, Chartered Accountants (Firm Registration No. 101049W/E300004) as the Statutory Auditors of the Company, to hold office for a term of five consecutive years commencing from the conclusion of this Annual General Meeting till the conclusion of the Annual General Meeting of the Company to be held in the financial year 2031-32, at a remuneration of ₹ 63,50,000/- (Indian Rupees Sixty Three Lakhs Fifty Thousand only) for the 2026-2027, payable in one or more tranches, excluding applicable taxes and reimbursement of out-of-pocket expenses incurred in connection with the audit of the accounts of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company and/or any Director of the Company and/or Mr. Mohammed Gawir Baig, Chief Financial Officer and/or Ms. Divya Prasad, Company Secretary and Compliance Officer, be and are hereby severally authorised to do all such acts, deeds, matters and things as may be deemed necessary, desirable, proper or expedient to give effect to this resolution, including finalising the terms and conditions of appointment and revision of remunerations, if any, during the tenure of the appointment, filing necessary forms and returns with the Registrar of Companies and other regulatory authorities, and to settle any question, difficulty or doubt that may arise in this regard.”

SPECIAL BUSINESS:

5. TO APPROVE THE CONTINUATION OF MR. RAVIKANT UPPAL (DIN: 00025970) AS NON-EXECUTIVE INDEPENDENT DIRECTOR UPON ATTAINING THE AGE OF 75 YEARS

*To consider and if thought fit, to pass the following resolution as a **Special Resolution**:*

“**RESOLVED THAT** pursuant to the provisions of Regulation 17(1A) and other applicable provisions, if any, of the SEBI

(Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), as amended from time to time, and other applicable laws, rules and regulations, including any statutory modification(s), amendment(s), clarification(s), re-enactment(s) or substitution(s) thereof for the time being in force and as recommended by the Nomination and Remuneration Committee and the Board of Directors, approval of the Members of the Company be and is hereby accorded for the continuation of Mr. Ravikant Uppal (DIN: 00025970) as a Non-Executive Independent Director of the Company, upon attaining the age of seventy-five (75) years, for the remaining period of his current term of appointment ending on September 26, 2029, as approved by the Members of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company has noted that Mr. Ravikant Uppal fulfils the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI LODR and has submitted the necessary declarations and confirmations in this regard.

RESOLVED FURTHER THAT the Board of Directors of the Company and/or any Director of the Company and/or Mr. Mohammed Gawir Baig, Chief Financial Officer and/or Ms. Divya Prasad, Company Secretary and Compliance Officer, be and are hereby severally authorised to do all such acts, deeds, matters and things and take all such steps as may be necessary, proper or expedient to give effect to this resolution, including filing necessary forms and intimations with the regulatory authorities and stock exchanges.”

6. TO APPROVE THE COMMISSION PAYABLE TO INDEPENDENT DIRECTORS

*To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:*

“RESOLVED THAT pursuant to the provisions of Section 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 (“Act”) read with the rules made thereunder, Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, if any, including any statutory modification(s), amendment(s), clarification(s), re-enactment(s) or substitution(s) thereof for the time being in force, and pursuant to the recommendation of the Board of Directors, approval of the Members of the Company be and is hereby accorded for payment of remuneration by way of commission to the Non-Executive Independent Directors of the Company, such amount and in such manner as may be determined by the Board on the

recommendation of Nomination and Remuneration Committee, provided that the total commission payable in any financial year shall not exceed one percent (1%) of the net profits of the Company, computed in accordance with the provisions of Section 198 of the Act.

RESOLVED FURTHER THAT the aforesaid remuneration by way of commission shall be in addition to the sitting fees payable to the Non-Executive Independent Directors for attending meetings of the Board of Directors and Committees thereof, and reimbursement of expenses for participation in the meetings.

RESOLVED FURTHER THAT the Board of Directors of the Company on the recommendation of the Nomination and Remuneration Committee be and is hereby authorised to determine, from time to time, the quantum of commission payable to each of the Non-Executive Independent Directors and the manner of distribution thereof, within the overall limits approved by the Members and in such manner as the Board may deem fit, having regard to the performance, roles, responsibilities and contribution of the respective Directors.

RESOLVED FURTHER THAT any Director of the Company and/or Mr. Mohammed Gawir Baig, Chief Financial Officer and/or Ms. Divya Prasad, Company Secretary and Compliance Officer, be and are hereby severally authorised to do all such acts, deeds, matters and things and to take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

7. TO APPROVE THE INCREASE IN PAYMENT OF REMUNERATION TO RELATED PARTIES, HOLDING AN OFFICE OR PLACE OF PROFIT

*To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:*

“RESOLVED THAT pursuant to the provisions of 188(1) (f) of the Companies Act, 2013, read with Rule 15 of the Companies (Meetings of the Board and its Powers) Rules, 2014, and other applicable provisions (including any amendments or statutory modifications thereto) and Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and pursuant to the recommendation of the Nomination and Remuneration Committee and the approval of Audit Committee and Board of Directors, the consent of the Members be and are hereby accorded for payment of remuneration to employees of the Company (including salary, perquisite, allowance and benefits) plus other benefits in accordance with the policy of the Company, who are the relatives of the directors, with effect from April 1, 2026 as per the details set out below:

(₹) In Millions

Sl. No.	Name	Designation	Category	Proposed Remuneration
				Fixed
1	Ishaan Bhardwaj	Vice President	Senior Management Personnel/ Promoter	15.00
2	Krithika Ganesh	Deputy Manager	Promoter Group	3.75
3	Keerthana Ravindra	Deputy Manager	Promoter Group	3.35

RESOLVED FURTHER THAT any Director of the Company and/or Mr. Mohammed Gawir Baig, Chief Financial Officer and/or Ms. Divya Prasad, Company Secretary and Compliance Officer, be and are hereby severally authorised to do all such acts, deeds, matters and things and to take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

8. TO APPROVE THE UPSIDE SHARING ARRANGEMENT WITH VIRIDITY TONE LLP

*To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**:*

“**RESOLVED THAT** pursuant to the provisions of Regulation 26(6) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“SEBI LODR Regulations”), the provisions of the Shareholders’ Agreement dated March 01, 2021 (as amended pursuant to the Waiver-cum-Amendment Agreement dated December 30, 2024) (“SHA”), and other applicable laws, if any, and subject to such approvals, consents, permissions and sanctions as may be necessary, the approval of the Members of the Company be and is hereby accorded to the Upside Sharing Arrangement, pursuant to which, the gains realised by Viridity Tone LLP (“Investor”) from divestment of its shareholding in the Company, in excess of the agreed threshold, shall be shared with Dr. Ajay Bhardwaj, Dr. Ganesh Sambasivam and Mr. K Ravindra Chandrappa, (“the identified Promoters”), in accordance with the terms of the SHA.

RESOLVED FURTHER THAT any Director of the Company and/or Mr. Mohammed Gawir Baig, Chief Financial Officer and/or Ms. Divya Prasad, Company Secretary and Compliance Officer, be and are hereby severally authorised to do all such acts, deeds and things as may be necessary to give effect to this resolution.”

By Order of the Board of Directors
For **Anthem Biosciences Limited**,

Sd/-

Divya Prasad

Company Secretary & Compliance Officer
Membership No. A41438

Place: Bangalore
Date: May 19, 2026

NOTES:

1. Pursuant to the General Circular No. 3/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs (MCA) and other Circulars issued from time to time by MCA, SEBI (hereinafter collectively referred to as “the Circulars”), companies are allowed to hold AGM through VC/OAVM, without the physical presence of Members at a common venue. Hence, in compliance with the Circulars, the AGM of the Company is being held through VC. The deemed venue for the AGM shall be the registered office of the Company.
2. In accordance with the aforesaid MCA Circulars and Circular Nos. SEBI/ HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, SEBI/HO/CFD/ CMD2/CIR/P/2021/11 dated January 15, 2021, SEBI/HO/CFD/CMD2/ CIR/P/2022/62 dated May 13, 2022, SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/ CIR/2023/167 dated October 7, 2023 issued by Securities Exchange Board of India (collectively referred to as “SEBI Circulars”), the Notice of the AGM along with the Annual Report for FY 2025-26 is being sent by electronic mode to those Members whose e-mail addresses are registered with the Company/National Securities Depository Limited (“NSDL”) and the Central Depository Services (India) Limited (“CDSL”), collectively “Depositories”.
3. The Notice along with the Annual Report for FY 2025-26 will be sent through e-mail to those Members whose name will appear in the register of beneficial Owners as on June 26, 2026. In case any Member is desirous of obtaining a hard copy of the Annual Report for the FY 2025-26 of the Company, he/she may send a request to the Company’s e-mail address at investors.abl@anthembio.com mentioning Folio No./DP ID and Client ID.
4. The Explanatory Statement pursuant to Section 102 of the Act setting out material facts concerning the Ordinary business under Item No. 4 and Special businesses under Item Nos. 5 to 8 of the Notice, is annexed hereto and additional information, pursuant to Regulation 36 of the LODR Regulations, in respect of the directors seeking appointment / reappointment at the AGM, forms part of this Notice.
5. Company has appointed KFin Technologies Limited (“KFinTech”), Registrars and Share Transfer Agents (“RTA”), to provide VC/OAVM facility for the AGM of the Company.
6. Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.
7. The attendance of the Members participating in the 20th AGM through VC/OAVM facility using their login credentials shall be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
8. Only bona-fide Members of the Company whose names appear on the Register of Beneficial Owners, will be permitted to attend the AGM through VC/ OAVM. The Company reserves the right to take all necessary steps as may be deemed necessary to restrict non-Members from attending the meeting
9. The facility for joining AGM through VC/OVAM will be available on a first come first serve basis. Members can login and join 30 (thirty) minutes prior to the scheduled time of meeting and window for joining shall be kept open till the expiry of 15 (fifteen) minutes after the scheduled time.
10. Institutional / Corporate Shareholders (i.e. other than individuals / HUF, NRI, etc.) are required to send a scanned copy (PDF/ JPG Format) of their Board or governing body Resolution/ Authorization etc., authorizing their representative to attend the AGM through VC / OAVM on their behalf and to vote through remote e-voting. The said Resolution/Authorization shall be sent to the Scrutinizer by email through the registered email address of the Institutional / Corporate Shareholders at email info@bmpandco.com with a copy marked to evoting@kfintech.com and investors.abl@anthembio.com. The scanned image of the above-mentioned documents should be in the naming format “Corporate Name Even No.” The documents should reach the Scrutinizer on or before 5:00 PM IST on July 21, 2026. Institutional shareholders, who are Members of the Company, are encouraged to attend and vote at the AGM through VC/OAVM facility.
11. In the case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.
12. The Register of Directors and Key Managerial Personnel and their Shareholding maintained under Section 170 of the Act and the Register of Contracts or Arrangements in which the Directors are interested maintained under Section 189 of the Act will be available for inspection by the Members. Members who wish to inspect may send their request through an email at investors.abl@anthembio.com up to the date of the 20th AGM.
13. All documents referred to in the accompanying Notice of the 20th AGM shall be open for inspection at the Registered Office of the Company/Electronic mode during normal business hours on all working days except Saturdays and Sundays, up to and including the date of the AGM of the Company. Members who wish to inspect may send their request through an email at investors.abl@anthembio.com to the date of the AGM.
14. Members holding shares in Electronic (demat) form are advised to inform the particulars of their bank account, change of postal address and email address to their respective Depository Participants only. The Company or its RTA shall not act on any request received directly from the Members holding shares in demat mode for changes in any bank mandates or other particulars.
15. Members are requested to quote their DPID & Client ID or Folio details respectively in all correspondences, including dividend matters to KFin Technologies Limited (Unit: Anthem Biosciences Limited), Plot 31- 32, Selenium, Tower B, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500 032 or the Secretarial

Department of the Company. The Dividend will be paid through the Electronic Clearing System (ECS) In accordance with relevant SEBI Circulars.

16. Members holding shares in Electronic (demat) form who have not registered their email IDs with the depository participants, are requested to register their email address with their depository participants.
17. In compliance with the MCA Circulars and Regulation 36(1)(a) of the Listing Regulations, Notice of the AGM along with the Annual Report for the financial year 2025-26 is being sent only through electronic mode to those members whose e-mail address is registered with the Company / Registrar and Transfer Agent / Depository Participants / Depositories. Further, in compliance with Regulation 36(1)(b) of the Listing Regulations, a letter providing the web-link, including the exact path, where Annual Report for the financial year 2025-26 is available, is being sent to those members whose e-mail address is not registered with the Company / Registrar and Transfer Agent / Depository Participants / Depositories. Members may note that the Notice of the 20th AGM and the Annual Report 2025-26 will also be available on the Company's website <https://anthembio.com/> and websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively, and on the website of Kfintech at <https://evoting.kfintech.com/public/Downloads.aspx>
18. The Company has fixed Friday, July 17, 2026 as the cut-off date for determining the eligibility of Members to vote through remote e-voting and e-voting during the AGM. Only those Members whose names appear in the List of Beneficial Owners as on the cut-off date, i.e., Friday, July 17, 2026, shall be entitled to vote on the resolutions set out in this Notice. The remote e-voting shall remain open for a period of 3 days commencing from Sunday, July 19, 2026 (9:00 AM IST) to Tuesday, July 21, 2026 (5:00 PM IST) (both days inclusive). The e-voting module shall be disabled for voting thereafter. Any person who is not a Member as on the cut-off date should treat this Notice for information purposes only.
19. Any person who acquires shares and becomes a Member of the Company after the Notice is sent and holding shares as on the cut-off date, i.e. July 17, 2026, may obtain the login ID and password by sending a request to evoting@kfintech.com/einward.ris@kfintech.com. However, if he / she is already registered for remote e-voting, then he / she can use his / her existing user ID and password for casting the vote.
20. The Company has appointed Mr. Pramod, (S M) Practicing, Partner of M/s BMP & Co LLP, Practicing Company Secretaries (FCS: 7834; CP: 13783) and in his absence Mr. Biswajit Ghosh, Practicing Company Secretary, Bengaluru (FCS: 8750; CP: 8239), Partner of the same firm as Scrutinizer to scrutinize the e-voting process in fair and transparent manner. The Scrutinizer will submit his report to the Chairman of the Company ("the Chairman") or to any other person authorized by the Chairman after the completion of the scrutiny of the e-voting (votes cast during the AGM and votes cast through remote e-voting), not later than 48 hours from the conclusion of the AGM. The result declared along with the Scrutinizer's report shall be communicated to the stock exchanges, NSDL and RTA, and will also be displayed on the Company's website.
21. As per Section 124(5) of the Act, the dividend which remains unpaid or unclaimed for a period of seven years from the date of its transfer to the unpaid dividend account, is liable to be transferred by the Company to the "Investor Education Protection Fund" (IEPF) established by the Central Government under the provisions of Section 125 of the Act. In terms of the foregoing provisions of the Act, there is no dividend which remains outstanding or remains unpaid and required to be transferred to the IEPF by the Company during the financial year.
22. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.
23. The details of the process and manner for participating in the 20th AGM through VC/OAVM are explained below:
 - a. Members may attend the AGM through a video conferencing platform provided by KFin Technologies Limited. Members may access the same at <https://emeetings.kfintech.com> and click on the "video conference" and access Members login by using the remote e-voting credentials. The link for AGM will be available in Members login where the EVEN and the name of the company can be selected.
 - b. Please note that the Members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the instructions provided in the "Other Instructions" mentioned in the notice.
 - c. Please note that participants connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
 - d. Questions and Queries: Members who may want to express their views or ask questions at the AGM may visit <https://emeetings.kfintech.com> and click on the tab "Post Your Queries Here" to write your queries in the window provided, by mentioning their name, demat account number/folio number, email ID and mobile number. The window shall remain active during the remote e-voting period and shall be closed 24 hours before the time fixed for the AGM.
 - e. Speaker Registration: Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request from their registered e-mail address mentioning their name, DP ID and Client ID/Folio number, PAN, mobile number at investors.abl@anthembio.com from Sunday, July 19, 2026 (9:00 AM IST) to Monday, July 20, 2026 (5:00 PM hours IST). Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

- f. Members who have not cast their vote through remote e-voting shall be eligible to cast their vote through e-voting system available during the AGM. E-voting during the AGM is integrated with the VC platform. Members may click on the voting icon ('vote now') on the left side of the screen to cast their votes.

Members may refer to "INSTRUCTIONS FOR PARTICIPATING THROUGH VC" of this notice for further details on participating and e-voting.

DIVIDEND RELATED INFORMATION

- a. Final dividend for the financial year ended March 31, 2026, as recommended by the Board of Directors on May 19, 2026, if approved by the Members at the AGM, will be paid within 30 days from the date of shareholders' approval to those Members whose name appear on the Register of Beneficial Owners maintained by the Depositories as on Friday, June 26, 2026, which is fixed as the record date for this purpose.
- b. Members holding shares in electronic form are hereby informed that Bank particulars registered with their respective Depository Participant (DPs), with whom they maintain their demat accounts, will be used by the Company for payment of dividend.
- c. SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/ CIR/2021/655 dated November 3, 2021 (subsequently amended by Circular Nos. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/687 dated December 14, 2021, SEBI/HO/MIRSD/MIRSD-PoD-1/P/ CIR/2023/37 March 16, 2023 and SEBI/HO/MIRSD/POD-1/P/ CIR/2023/181 November 17, 2023) has mandated that with effect from April 1, 2024, shall be paid only through electronic mode.
- d. Members are requested to update their KYC with their depositories to enable receipt of dividend directly into their bank account on the payout date.
- e. Pursuant to the amendments made by the Finance Acts of the respective year, dividend paid by a company on or after April 1, 2020, is taxable in the hands of Members and the Company is required to deduct tax at source (TDS) / withholding tax from dividend paid to Members at the prescribed rates. The Members are requested to update their PAN, address, category, and residential status with DPs (in case of shares held in demat mode). SEBI has also mandated the submission of the Permanent Account Number (PAN) by every participant in the securities market.

I. For Resident Shareholders

Tax is required to be deducted at source under Section 393(1) [Table Sr. No. 7] read with Section 393(4) [Table Sr. No. 10] of the Act, at the rate of 10% on the amount of dividend where Shareholders have registered their valid Permanent Account Number (PAN). In case, Shareholders do not have PAN/ have not registered their valid PAN details in their demat account/ PAN is invalid or declared to be inoperative on non-linking of PAN with Aadhaar,

TDS at the rate of 20% shall be deducted under Section 397 of the Act.

a. Resident Individuals

No tax shall be deducted on dividend payable to resident individuals if:

- i. Total dividend amount to be received by them during the Financial Year (FY) 2025-26 does not exceed ₹ 10,000; or
- ii. The Shareholder provides Form 121, provided that all the required eligibility conditions are met. Please note that all fields are mandatory to be filled up and the Company may at its sole discretion reject the form, if it does not fulfil the prescribed requirement under the Act. Click here to access [Form 121](#).
- iii. Exemption certificate is issued by the Income-tax Department, if any.

Form 121 must be furnished only where the dividend payable exceeds ₹ 10,000/-. Since the Company has declared a dividend of ₹. 2/- per share, the requirement to submit Form 121 will arise only for shareholders holding more than 5,000 shares.

b. Resident – Other than Individuals

No tax shall be deducted on dividend payable to the following resident -other than individuals where they provide details and documents. Click here to access [Resident Tax Declaration](#):

- i. **Insurance Companies:** Self declaration that it qualifies as 'Insurer' as per section 2(7A) of the Insurance Act, 1938 and has full beneficial interest with respect to the equity shares owned by it along with self-attested copy of PAN card and certificate of registration with Insurance Regulatory and Development Authority (IRDA)/ Life Insurance Corporation of India (LIC)/ General Insurance Corporation of India (GIC).
- ii. **Mutual Funds:** Self-declaration that it is registered with Securities and Exchange Board of India (SEBI) and is notified under Section 11 of Schedule VII [Table Sr. No. 20] of the Act along with self-attested copy of PAN card and certificate of registration with SEBI.
- iii. **Alternative Investment Fund (AIF):** Self-declaration that its income is exempt under Section 11 - Schedule V [Table Sr. No. 1] of the Act, and they are registered with SEBI as Category I or Category II AIF along with self-attested copy of the PAN card and certificate of AIF registration with SEBI.

- iv. **National Pension System (NPS) Trust:** Self-declaration that it qualifies as NPS Trust and income is eligible for exemption under Section 11 of Schedule VII [Table Sr. No. 41] of the Act and being regulated by the provisions of the Indian Trusts Act, 1882 along with self-attested copy of the PAN card.
- v. **Recognized Provident Fund:** Self-declaration that it qualifies as a Recognized Provident Fund along with self-attested valid documentary evidence (e.g., relevant copy of registration, notification, order, etc.) in support of the provident fund being established under a scheme framed under the Employees Provident Funds Act, 1952.
- vi. **Approved Superannuation Fund / Approved Gratuity Fund:** Self-declaration that it qualifies as Approved Superannuation/Gratuity Fund along with self-attested copy of a valid approval granted by the Commissioner (i) under Rule 2 of Part B of Fourth Schedule to the Act (In case of Approved Superannuation Fund) under Rule 2 of Part C of Fourth Schedule to the Act (In case of Approved Gratuity Fund).
- vii. **Other Non-Individual Shareholders:** Self-attested copy of documentary evidence supporting the exemption along with self-attested copy of PAN card.

Click here to access the for the [Non-Resident Tax Declaration](#).

- II. Self-attested copy of Tax Residency Certificate (TRC) for the financial year 2026-27 obtained from the tax authorities of the country of which the Shareholder is a resident.
- III. E-filed Form 41 (filed electronically on the Indian Income Tax web portal pursuant to Notification no. 03/2022 dated July 16, 2022) valid for the period April 2026 to March 2027.
- IV. Self-declaration by Shareholder of meeting treaty eligibility requirement and satisfying beneficial ownership requirement (financial year April 1, 2026 to March 31, 2027). Click here to access [Non-Resident Tax Declaration](#) (Required only where Tax treaty benefit needs to be availed).
- V. In case of Foreign Institutional Investors and Foreign Portfolio Investors, copy of SEBI registration certificate.
- VI. In case of Shareholder being tax resident of Singapore, please furnish the letter issued by the competent authority or any other evidence demonstrating the non-applicability of Article 24 - Limitation of Relief under India-Singapore DTAA.

II. For Non-resident Shareholders

a. As per Domestic Tax Law

Taxes are required to be withheld in accordance with the provisions of Section 393(2) [Table Sr. No. 17 and 15] of the Act at the applicable rates. As per the relevant provisions of the Act, the dividend income payable to the non-resident shareholders shall be subject to withholding tax at the rate of 20% (plus applicable surcharge and cess) on the amount of dividend payable to them.

b. As per Double Tax Avoidance Agreement (DTAA)

As per Section 159 of the Act, the non-resident Shareholder has the option to be governed by the provisions of the DTAA between India and the country of tax residence of the Shareholder, if they are more beneficial to them. For this purpose, i.e. to avail DTAA benefit, the non-resident Shareholders are required to submit the following:

- I. Self-attested copy of the PAN card allotted by the Indian Income Tax authorities. In case, PAN is not available, the non-resident shareholder shall furnish (a) name, (b) email id, (c) contact number, (d) address in residency country, (f) Tax Identification Number of the residency country as per format prescribed under rule 37BC of Income-tax Rules, 1962.

It is recommended that Shareholders should independently satisfy their eligibility to claim DTAA benefit including meeting of all conditions laid down by DTAA.

Kindly note that the Company is not obligated to apply beneficial DTAA rates at the time of tax deduction /withholding on dividend amounts. Application of beneficial rate as per DTAA for the purpose of withholding taxes shall depend upon completeness and satisfactory review by the Company of the documents submitted by the non-resident Shareholder.

III. Lower Withholdings as per Certificate under Section 395

In the case of resident as well as non-resident shareholders, where a certificate issued under Section 395 of the Income-tax Act, 2025 for deduction of tax at a lower rate or nil rate is furnished, tax shall be withheld at the rate specified in such certificate, subject to submission of a self-attested copy of the valid certificate to the Company.

PAYMENT OF DIVIDEND

The dividend on Equity Shares for FY 2025-26, once approved by the Shareholders of the Company at the AGM, will be paid after deducting the tax at source. The following provisions under the Act will also be considered to determine the applicable TDS rate:

a. TDS to be deducted at higher rate in case of non-linkage of PAN with Aadhaar

As per Section 262 of the Act, every person who has been allotted a PAN and who is eligible to obtain Aadhaar, shall be required to link the PAN with Aadhaar. In case of failure to comply with this, the PAN allotted shall be deemed to be invalid/inoperative and tax shall be deducted at the rate of 20% as per the provisions of Section 397 of the Act.

Shareholders may visit <https://www.incometax.gov.in/iec/foportal/> for FAQ issued by the Government on PAN Aadhar linking.

b. Declaration under Rule 203 of the Income Tax Rules, 2026 (the “Rules”)

In terms of Rule 203 of the Income Tax Rules, 2026, if dividend income on which tax has been deducted at source is assessable in the hands of a person other than the deductee, then such deductee should file declaration with Company in the manner prescribed in the Rules. Click here to access the [Format of declaration](#) and [Appendix](#) for Rule 203.

c. For Shareholders having multiple accounts under different status / category

Shareholders holding Equity Shares under multiple accounts under different status / category and single PAN, may note that higher of the tax as applicable to the status in which shares held under a PAN will be considered on their entire holding in different accounts.

Shareholders may visit <https://www.incometax.gov.in/iec/foportal/> for FAQ issued by the Government on PAN Aadhar linking.

a. Declaration under Rule 203 of the Income Tax Rules, 2026 (the “Rules”)

In terms of Rule 203 of the Income Tax Rules, 2026, if dividend income on which tax has been deducted at source is assessable in the hands of a person other than the deductee, then such deductee should file declaration with Company in the manner prescribed in the Rules. Click here to access the [Format of declaration](#) and [Appendix](#) for Rule 203.

b. For Shareholders having multiple accounts under different status / category

Shareholders holding Equity Shares under multiple accounts under different status / category and single PAN, may note that higher of the tax as applicable to the status in

which shares held under a PAN will be considered on their entire holding in different accounts.

UPDATE OF BANK ACCOUNT DETAILS:

Pursuant to the recent amendment to Regulation 12 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, the Company is mandated to pay the dividend only through electronic mode as prescribed under aforesaid regulation.

Accordingly, shareholders are requested to update their bank account details with their depositories participants for the shares held in dematerialized form.

SUBMISSION OF TAX RELATED DOCUMENTS:

The documents such as Form 121 and documents under Sections 393(5) can be uploaded on the link <https://ris.kfintech.com/form15> on or before Wednesday, July 15, 2026 to enable the Company to determine the appropriate TDS / withholding tax rate applicable. Any communication on the tax determination/deduction received post Wednesday, July 15, 2026 shall not be considered.

The aforementioned documents are required to be shared with the Company at investors.abl@anthembio.com on or before July 15, 2026. Members are requested to visit <https://anthembio.com/wp-content/uploads/2026/06/Communication-on-Tax-Deduction-at-Source-on-Dividend.pdf> for more instructions and information on this subject. No communication would be accepted from Members after July 15, 2026, regarding tax-withholding matters. Shareholders may write to investors.abl@anthembio.com for any clarifications on this subject.

Shareholders can check their tax credit in Form 168 (erstwhile Form 26AS) from the e-filing account at <https://www.incometax.gov.in/iec/foportal/>.

The above tax rates are indicative in nature. For specific rates, Members may refer to their tax consultant.

By Order of the Board of Directors
For **Anthem Biosciences Limited**,

Sd/-

Divya Prasad

Place: Bangalore
Date: May 19, 2026

Company Secretary & Compliance Officer
Membership No. A41438

EXPLANATORY STATEMENT

UNDER SECTION 102 OF THE COMPANIES ACT, 2013

Item 4:

TO APPOINT M/S. S.R. BATLIBOI & ASSOCIATES LLP, CHARTERED ACCOUNTANTS, (FRN 101049W/E300004) AS THE STATUTORY AUDITORS OF THE COMPANY

The Members of the Company at the Annual General Meeting held on September 27, 2024 had appointed M/s. K.P. Rao & Co., Chartered Accountants (Firm Registration No. 003135S), as the Statutory Auditors of the Company to hold office until the conclusion of the Annual General Meeting to be held for the financial year 2025-26.

In view of the Company's status as a listed entity and its evolving business and regulatory environment, the Audit Committee undertook an evaluation of the Company's audit requirements and the suitability of audit firms capable of effectively servicing the Company's present and future requirements.

As part of its evaluation process, the Audit Committee considered various factors including the professional standing of the audit firm, experience in auditing large listed companies, industry expertise, quality control standards, peer review status, internal controls and independence, audit methodology, scope and approach, audit service delivery (transition and timelines), technological capabilities, availability of specialist resources and overall ability to meet the Company's audit and reporting requirements. The Audit Committee also reviewed the proposed audit approach and engagement structure to ensure continuity, effectiveness and quality of the statutory audit process.

Based on the aforesaid evaluation, the Audit Committee recommended the appointment of M/s. S.R. Batliboi & Associates LLP, Chartered Accountants (Firm Registration No. 101049W/E300004), as the Statutory Auditors of the Company. The Board of Directors, at its meeting held on April 22, 2026, after considering the recommendation of the Audit Committee, approved the appointment of M/s. S.R. Batliboi & Associates LLP as the Statutory Auditors of the Company, subject to the approval of the Members.

M/s. S.R. Batliboi & Associates LLP is a leading firm of Chartered Accountants in India and a Member firm of the EY Global network. The firm has extensive experience in providing audit and assurance services to large listed and multinational companies across diverse sectors and has established systems relating to audit quality, risk management, professional standards and independence. The firm holds a valid Peer Review Certificate issued by the Peer Review Board of the Institute of Chartered Accountants of India.

The Board believes that the experience, expertise and resources of M/s. S.R. Batliboi & Associates LLP would contribute to the continued enhancement of the Company's audit processes and support its commitment to maintaining high standards of financial reporting, transparency, governance and compliance.

The proposed appointment shall be for a term of five consecutive years commencing from the conclusion of this Annual General Meeting until the conclusion of the Annual General Meeting to be held in the financial year 2031-32.

Based on the recommendation of the Audit Committee, the Board has approved remuneration of ₹ 63,50,000 (Indian Rupees Sixty-Three Lakhs Fifty Thousand only) excluding applicable taxes and reimbursement of out-of-pocket expenses incurred in connection with the audit for the financial year 2026-27. While recommending the remuneration, the Audit Committee considered various factors including the scope of audit, size and complexity of the Company's operations, reporting obligations applicable to a listed entity, audit effort involved and industry benchmarks. The remuneration for the subsequent years shall be determined by the Board of Directors based on the recommendation of the Audit Committee, taking into account the scope and requirements of the audit from time to time.

The Company has received the written consent and eligibility certificate from M/s. S.R. Batliboi & Associates LLP confirming that their appointment, if made, would be in accordance with the provisions of Sections 139, 141 and other applicable provisions of the Companies Act, 2013 and the rules made thereunder. The firm has further confirmed that it is not disqualified from being appointed as the Statutory Auditors of the Company and satisfies the criteria prescribed under the Companies Act, 2013 and other applicable laws.

None of the Directors, Key Managerial Personnel of the Company or their relatives is concerned or interested, financially or otherwise, in the resolution.

The Board of Directors is of the opinion that the appointment of M/s. S.R. Batliboi & Associates LLP as the Statutory Auditors of the Company is in the best interest of the Company and recommends the Ordinary Resolution as set out at Item No. 4 of the Notice for approval of the Members.

Item No.5:

TO APPROVE THE CONTINUATION OF MR. RAVIKANT UPPAL (DIN: 00025970) AS NON-EXECUTIVE INDEPENDENT DIRECTOR UPON ATTAINING THE AGE OF 75 YEARS

Mr. Ravikant Uppal (DIN: 00025970) was appointed as a Non-Executive Independent Director of the Company by the Members at the Annual General Meeting held on September 27, 2024, to hold office for a term of five consecutive years up to September 26, 2029.

In terms of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, continuation of directorship of a Non-Executive Director upon attaining the age of seventy-five (75) years requires approval of the Members by way of a special resolution. Mr. Ravikant Uppal will attain the age of 75 years on May 9, 2027 and accordingly, approval of the Members is being sought for continuation of his directorship as an Independent Director for the remainder of his current term ending on September 26, 2029.

The Board has reviewed the continued association of Mr. Uppal and, taking into account his extensive industry experience, independent perspective and valuable contributions to the deliberations of the Board, is of the view that his continuation as an Independent Director

would be beneficial to the Company. The Board believes that his guidance and oversight will continue to support the Company in pursuing its long-term strategic objectives while maintaining high standards of governance.

The brief profile and other details of Mr. Uppal, as required under the Companies Act, 2013, Secretarial Standard-2 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided below:

Particulars	Details
Name	Mr. Ravikant Uppal
DIN	00025970
Date of Birth Age	May 09, 1952 74 Years
Qualification	Mr. Ravikant Uppal holds a degree of Bachelor of Technology in Mechanical Engineering from Indian Institute of Technology, Delhi. He is a graduate of the Wharton Advanced Management Program from The Wharton School, University of Pennsylvania. He also holds a postgraduate diploma in business administration issued by the Indian Institute of Management, Ahmedabad.
Experience (including experience in specific function areas)	Mr. Ravikant Uppal brings over 40 years of extensive experience across engineering, manufacturing, and infrastructure sectors, both in India and internationally. He has held several high-profile leadership positions, including Managing Director & Group CEO of Jindal Steel & Power, Whole-time Director of L&T Group, and MD & CEO (Power) at L&T. During his tenure with the ABB Group, he served in roles such as President of Global Markets and Member of the Group Executive Committee, as well as President of ABB in the Asia Pacific Region and Chairman & MD of ABB India. Additionally, he was the Founding Managing Director of Volvo in India. Mr. Uppal has significant international experience, having worked for over 15 years across Europe, the Middle East, North Africa, and Southeast Asia. Recently, he founded SISCOL, a venture focused on steel-based civil and industrial infrastructure in India.
Terms and condition for appointment	Appointed as Independent Director on terms and conditions as mentioned in the letter of appointment entered into between the Company and the Independent Director.
Remuneration Details	As determined by the Board from time to time not exceeding the limits provided under the Companies Act, 2013
Date of first appointment on the Board	Mr. Ravikant Uppal was appointed as a Non-Executive Independent Director by the shareholders in the Annual General meeting held on September 27, 2024. Details pertaining to his appointment, remuneration, and number of meetings attended are provided in the Corporate governance report of this Annual Report.
Shareholding in the Company/ Number of Equity Shares held in the Company for any other person on a beneficial basis	Nil
Relationship with other Directors, Manager and Key Managerial Personnel of the Company	Not related to any Director, Manager or Key Managerial Personnel
Number of meetings of the Board attended during the year	9
Directorships of other Boards	<ul style="list-style-type: none"> ● Steel Infra Solutions Company Limited ● Sicol Infra Private Limited ● Transport Corporation of India Limited ● Surin Automotive Private Limited
Membership / Chairmanship of committees in other companies	<ul style="list-style-type: none"> ● Chairman of Audit Committee of Transport Corporation of India Limited ● Member of Risk Management Committee of Transport Corporation of India Limited ● Member of Stakeholders Relationship Committee of Steel Infra Solutions Company Limited
Listed entities from which the Director has resigned in the past three years	NIL
Justification for choosing the appointees for appointment as Independent Director/ Skills and capabilities required for the role and the manner in which the proposed person meets such requirements	Mr. Ravikant Uppal, with a strong educational background from premier institutions like IIT Delhi, The Wharton School, and IIM Ahmedabad, brings over 40 years of diverse industry experience. His expertise spans technical operations, strategic leadership, and corporate governance, making him well-suited to provide valuable oversight and guidance. His experience of leading reputed large companies of the likes of Jindal Steel & Power, L&T, ABB, Volvo (India) and bringing in international experience having served in the Group Executive Committee and as President of ABB in the Asia Pacific Region will be beneficial for Anthem's growth in the global CRDMO space. As an Independent Director, Mr. Uppal's vast experience and impartial judgment would enhance the company's strategic direction, operational efficiency, and adherence to high standards of governance, driving long-term growth and innovation in the biosciences sector.

In the opinion of the Board, Mr. Uppal fulfils the criteria of independence prescribed under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and continues to be independent of the management and possesses appropriate skills, experience and knowledge. The Board considers that his association would be of immense benefit to the Company, and it is desirable to avail the expertise of Mr. Uppal as an Independent Director. He has submitted the requisite declarations and confirmations confirming that he meets the criteria of independence and that there are no circumstances or situations which impair, or are likely to impair, his ability to discharge his duties as an Independent Director.

Mr. Uppal and his relatives may be deemed to be concerned or interested in the resolution. None of the other Directors or Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested directly/indirectly, financially or otherwise, in the resolution.

The Board considers that the continuation of Mr. Ravikant Uppal as an Independent Director of the Company is in the best interests of the Company and accordingly recommends the Special Resolution as set out at Item No. 5 of the Notice for approval of the Members.

Item No.6

TO APPROVE THE COMMISSION PAYABLE TO INDEPENDENT DIRECTORS

The Independent Directors of the Company bring diverse expertise across business leadership, finance, law, governance, strategy and industry, and play a critical role in providing independent oversight and objective judgement in the discharge of the Board's responsibilities. Their role extends beyond attendance at Board and Committee meetings and includes active engagement in matters relating to corporate strategy, risk management, financial oversight, regulatory compliance, succession planning, stakeholder interests and long-term value creation.

The remuneration, including commission, payable to the existing Independent Directors is presently governed by approvals obtained at the time of their respective appointments. With a view to establish a uniform remuneration framework for all existing and future Independent Directors and avoiding the need for separate shareholder approvals upon changes in Board composition, approval of the Members is being sought for payment of remuneration in the form of commission, in aggregate, to the Independent Directors of the Company within the limits prescribed under applicable law.

In view of the enhanced responsibilities, accountability and time commitment expected of Independent Directors under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors, at its meeting held on May 19, 2026, approved and recommended the remuneration limits to the Independent Directors of the Company, subject to the approval of the Members.

Pursuant to Section 197 of the Companies Act, 2013, where a company has a Managing Director or Whole-time Director, the aggregate remuneration payable to all Non-Executive Directors by way of commission shall not exceed one percent (1%) of the net profits of the Company in any financial year, computed in accordance with Section 198 of the Act. The proposed commission shall be within the aforesaid statutory limit.

The approval sought from the Members enables payment of commission, in aggregate, not exceeding one percent (1%) of the net profits of the Company for each financial year, to the Independent Directors of the Company. The actual amount of commission payable, if any, and its distribution amongst the Independent Directors shall be determined by the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, having regard to factors such as their roles and responsibilities, Membership and chairmanship of Board Committees, participation in Board and Committee meetings, time devoted to the affairs of the Company, contribution to Board deliberations and overall contribution towards the governance and strategic oversight of the Company.

The approval proposed under this resolution shall apply to all existing Independent Directors as well as those who may be appointed from time to time and shall remain in force until modified or revoked by the Members. The approval does not create any entitlement in favour of any Independent Director and the payment of commission in any financial year shall remain subject to the recommendation of the Nomination and Remuneration Committee, approval of the Board, the financial performance of the Company and in compliance with applicable laws.

The commission, if paid, shall be in addition to the sitting fees payable for attending meetings of the Board and Committees thereof and reimbursement of expenses incurred in connection therewith, as permissible under applicable law. Payment of commission shall also be subject to the annual performance evaluation of the Independent Directors carried out in accordance with the provisions of the Companies Act, 2013 and Schedule IV and Nomination Remuneration Policy.

All the Independent Directors of the Company and their respective relatives may be deemed to be concerned or interested in the resolution. None of the other Directors, Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested directly/indirectly, financially or otherwise, in the resolution.

The Board is of the view that the proposed resolution would enable the Company to continue to attract, retain and appropriately compensate individuals of high caliber serving on its Board. Accordingly, the Board recommends the Ordinary Resolution as set out at Item No. 6 of the Notice for approval of the Members.

Item No.7

TO APPROVE THE INCREASE IN PAYMENT OF REMUNERATION TO RELATED PARTIES, HOLDING AN OFFICE OR PLACE OF PROFIT

Pursuant to Section 188(1)(f) of the Companies Act, 2013 read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, prior approval of the Members is required for the appointment of a related party to any office or place of profit in the Company where the monthly remuneration exceeds the prescribed threshold.

Mr. Ishaan Bhardwaj, Vice President, Ms. Krithika Ganesh, Deputy Manager, and Ms. Keerthana Ravindra, Deputy Manager, are employees of the Company and are related parties by virtue of their relationship with Directors of the Company. The Company proposes to pay remuneration to the aforesaid employees under Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and for the financial

year 2026-27 in excess of the threshold prescribed under Section 188(1)(f) of the Companies Act, 2013 and accordingly seeks the approval of the Members.

On the recommendation of the Nomination and Remuneration Committee, the Audit Committee reviewed the proposed remuneration and noted that the proposed remuneration is fair and reasonable and also commensurate with the roles and responsibilities of the concerned employees. Further, it is in line with the Company's remuneration philosophy and prevailing market practices. The Board of Directors, after considering the recommendations, approved the proposed remuneration and is satisfied that the arrangements are in the ordinary course of business and on an arm's length basis.

The proposed remuneration for the following employees exceeds the statutory threshold prescribed under Section 188(1)(f) of the Companies Act, 2013 and therefore requires approval of the Members:

Sl. No.	Name	Designation	Category	₹ in Millions	
				Proposed Remuneration	Fixed
1	Ishaan Bhardwaj	Vice President	Senior Management Personnel/ Promoter		15.00
2	Krithika Ganesh	Deputy Manager	Promoter Group		3.75
3	Keerthana Ravindra	Deputy Manager	Promoter Group		3.35

The disclosures required under Section 188(1)(f) of the Companies Act, 2013 read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 23 of the SEBI Listing Regulations read with SEBI Master circular dated June 11, 2023- Last updated on January 30, 2026, as placed before the Nomination and Remuneration Committee, Audit Committee and the Board, are set out below:

Sl. No	Particulars	Mr. Ishaan Bhardwaj	Ms. Krithika Ganesh	Ms. Keerthana Ravindra
1	The name of related party and nature of relationship	Name of the Related Party: Mr. Ishaan Bhardwaj – Vice President, is also designated as a member of the Senior Management Personnel and is also the Promoter of the Company. Nature of relationship: Mr. Ishaan Bhardwaj is son of Mr. Ajay Bhardwaj, Managing Director & Chief Executive Officer of the Company. Accordingly, Mr. Ishaan Bhardwaj qualifies as a related party	Name of the Related Party: Ms. Krithika Ganesh- Deputy Manager, is also a member of Promoter Group. Nature of relationship: Ms. Krithika Ganesh is daughter of Dr. Ganesh Sambasivam, Whole Time Director of the Company. Accordingly, Ms. Krithika Ganesh qualifies as a related party.	Name of the Related Party: Ms. Keerthana Ravindra– Deputy Manager is also a member of Promoter Group. Nature of relationship: Ms. Keerthana Ravindra is daughter of Mr. K Ravindra Chandrappa, Whole-Time Director of the Company. Accordingly, Ms. Keerthana Ravindra qualifies as a related party
2	the nature, duration of the contract and particulars of the contract or arrangement;	The said revised remuneration is for the period of 1 year starting April 1, 2026 to March 31, 2027. The revision in annual remuneration of Mr. Ishaan Bhardwaj is as applicable to other employees of the Company. No specific contract or arrangement has been entered.	The said revised remuneration is for the period of 1 year starting April 1, 2026, to March 31, 2027. The revision in annual remuneration of Ms. Krithika Ganesh is as applicable to other employees of the Company. No specific contract or arrangement has been entered.	The said revised remuneration is for the period of 1 year starting April 1, 2026 to March 31, 2027. The revision in annual remuneration of Ms. Keerthana Ravindra is as applicable to other employees of the Company. No specific contract or arrangement has been entered
3	the material terms of the contract or arrangement including the value, if any;	<ul style="list-style-type: none"> Revised annual Remuneration of ₹ 15.00 Millions is for the FY 2026-27 Other benefits as per Company Policies 	<ul style="list-style-type: none"> Revised annual Remuneration of ₹ 3.75 Millions is for the FY 2026-27 Other benefits as per Company Policies 	<ul style="list-style-type: none"> Revised annual Remuneration of ₹ 3.35 Millions is for the FY 2026-27 Other benefits as per Company Policies
4	any advance paid or received for the contract or arrangement, if any;	No advance paid or received in connection with this arrangement	No advance paid or received in connection with this arrangement	No advance paid or received in connection with this arrangement

Sl. No	Particulars	Mr. Ishaan Bhardwaj	Ms. Krithika Ganesh	Ms. Keerthana Ravindra
5	the manner of determining the pricing and other commercial terms, both included as part of contract and not considered as part of the contract;	The revised remuneration is determined based with reference to current industry standards.	The revised remuneration is determined based with reference to current industry standards.	The revised remuneration is determined based with reference to current industry standards
6	whether all factors relevant to the contract have been considered, if not, the details of factors not considered with the rationale for not considering those factors; and	All relevant factors to the arrangement are considered.	All relevant factors to the arrangement are considered.	All relevant factors to the arrangement are considered
7	The percentage of the listed entity's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction	0.07% on the consolidated turnover of the Company for the financial year ended March 31, 2026.	0.02% on the consolidated turnover of the Company for the financial year ended March 31, 2026.	0.02% on the consolidated turnover of the Company for the financial year ended March 31, 2026.
8	Justification as to why the RPT is in the interest of the listed entity	<p>In FY 2024-25, Mr. Bhardwaj successfully led the Company's biology operations.</p> <p>In FY 2025-26, in addition to biology operations role, he has been additionally entrusted with heading procurement for the CRDMO (Contract Research, Development & Manufacturing Organisation) business – a responsibility critical to ensuring supply chain reliability and cost optimization. Having taken the additional responsibility, under his leadership, better vendor terms have been negotiated, resulting in procurement efficiency improved significantly and reduction in lead times for critical raw materials. Raw Material Margins as a %age of revenue from operations on a consolidated basis has improved under his leadership from 59.7% in FY 2024-25 to 61.8% in FY 2025-26.</p> <p>As Head of Biology Operations:</p> <ul style="list-style-type: none"> Ishaan has been instrumental in increasing manufacturing output of Serratiopeptidase (which is Anthem's largest Specialty Ingredients product) by 50% with existing infrastructure and has also initiated manufacturing at Unit II through fermentation at 30 KL scale of Vitamin K2 MK7 (a leading Specialty Ingredients product for Anthem). 	<p>In her current role, Ms. Krithika Ganesh serves as a primary client interface, managing large pharmaceutical client programmes and ensuring effective communication, coordination, and delivery.</p> <p>In addition to the current role she has been given a Project management responsibility ensuring smooth end to end completion of client deliverables and shipments and is working on green chemistry programmes, miscellar chemistry, metal mediator catalyst and pincer catalyst programme</p> <p>Her contributions have resulted in improved client satisfaction scores and enhanced delivery timelines, strengthening client relationships and repeat business opportunities.</p>	<p>In her current role, Ms. Keerthana Ravindra's responsibilities span financial analysis, sustainability and ESG-related programs, as well as the preparation and coordination of corporate disclosures and reporting requirements. She has been involved closely in the Company's reporting and compliance activities following its listing on the Stock Exchange.</p> <p>Keerthana, holds a Bachelor of Commerce (Honors) degree and has successfully completed the CISI Level I Certification. She has also completed a course on ESG compliance from the Indian Institute of Management, Bangalore (IIM Bangalore). Her multidisciplinary experience across finance, sustainability and corporate reporting enables her to support strategic decision-making and contribute to long-term value creation within the organization.</p> <p>Since joining the Company, she has played an active role in supporting key management initiatives across financial analysis, ESG and corporate reporting.</p>

Sl. No	Particulars	Mr. Ishaan Bhardwaj	Ms. Krithika Ganesh	Ms. Keerthana Ravindra
		<ul style="list-style-type: none"> Under his leadership, the fermentation facility at Unit III is very close to commissioning, which will add ~40 KL of upstream capacity for microbial fermentation. <p>In addition to his current responsibility, for FY 2026-27, he is also taking additional responsibility for driving the strategic investment of Unit III towards large scale mammalian fermentation single use facility for drug substance manufacturing of novel biologics and biosimilar for regulated markets and a drug product facility which will be Anthem's first foray into finished formulations.</p> <p>The proposed revision includes an increase in total remuneration from ₹ 12 Millions to ₹ 15 Millions per annum w.e.f. April 01, 2026. This increase is in alignment with the Company's performance.</p>	<p>The proposed revision includes an increase in total from ₹ 3.10 Millions to ₹ 3.75 Millions per annum w.e.f. April 01, 2026, which remains consistent with market standards for comparable roles and responsibilities and is in alignment with the Company's performance.</p>	<p>The proposed revision includes an increase in total from ₹ 2.80 Millions to ₹ 3.35 Millions per annum w.e.f. April 01, 2026, which remains consistent with market standards for comparable roles and responsibilities and is in alignment with the Company's performance.</p>
9	Where the transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary	No	No	No
10	A statement that the valuation or other external report, if any, relied upon by the listed entity in relation to the proposed transaction	The proposed remuneration has been determined by the Company based on performance, internal remuneration policies and Mercer Compensation benchmarking analysis. Valuation report or other external report from any third party has not been obtained for this purpose.	The proposed remuneration has been determined by the Company based on performance, internal remuneration policies and Mercer Compensation benchmarking analysis. Valuation report or other external report from any third party has not been obtained for this purpose.	The proposed remuneration has been determined by the Company based on performance, internal remuneration policies and Mercer Compensation benchmarking analysis. Valuation report or other external report from any third party has not been obtained for this purpose.

Sl. No	Particulars	Mr. Ishaan Bhardwaj	Ms. Krithika Ganesh	Ms. Keerthana Ravindra
11	any other information relevant or important for the Board to take a decision on the proposed transaction.	<p>Mr. Ishaan Bhardwaj is proposed to be paid an annual remuneration of ₹ 15.00 Millions for the FY 2026-27, determined on the basis of his annual performance evaluation.</p> <p>The remuneration was approved by the Board, based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, in its meetings held on May 18, 2026 and May 19, 2026 respectively.</p> <p>Since the proposed remuneration exceeds the threshold prescribed under Section 188(1)(f) of the Companies Act, 2013 and Regulation 23 of the SEBI Listing Regulations read with SEBI Master circular dated June 11, 2023- Last updated on January 30, 2026, it requires the prior approval of the shareholders.</p> <p>The arrangement is on an arm's length basis and is considered fair and reasonable.</p>	<p>Ms. Krithika Ganesh is proposed to be paid an annual remuneration of ₹ 3.75 Millions for the FY 2026-27, determined on the basis of her annual performance evaluation.</p> <p>The remuneration was approved by the Board, based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, in its meetings held on May 18, 2026 and May 19, 2026 respectively.</p> <p>Since the proposed remuneration exceeds the threshold prescribed under Section 188(1)(f) of the Companies Act, 2013 and Regulation 23 of the SEBI Listing Regulations read with SEBI Master circular dated June 11, 2023- Last updated on January 30, 2026, it requires the prior approval of the shareholders.</p> <p>The arrangement is on an arm's length basis and is considered fair and reasonable.</p>	<p>Ms. Keerthana Ravindra is proposed to be paid an annual remuneration of ₹ 3.35 Millions for the FY 2026-27, determined on the basis of her annual performance evaluation.</p> <p>The remuneration was approved by the Board, based on the recommendation of the Nomination and Remuneration Committee and the approval of the Audit Committee, in its meetings held on May 18, 2026 and May 19, 2026 respectively.</p> <p>Since the proposed remuneration exceeds the threshold prescribed under Section 188(1)(f) of the Companies Act, 2013 and Regulation 23 of the SEBI Listing Regulations read with SEBI Master circular dated June 11, 2023- Last updated on January 30, 2026, it requires the prior approval of the shareholders.</p> <p>The arrangement is on an arm's length basis and is considered fair and reasonable.</p>

The approval of the Members is being sought solely to comply with the requirements of Section 188(1)(f) of the Companies Act, 2013 on account of the remuneration exceeding the prescribed threshold. The Board confirms that the terms of employment, responsibilities discharged and remuneration payable to the aforesaid employees have been reviewed by the Nomination and Remuneration Committee, the Audit Committee and the Board and are considered to be fair, reasonable and at arm's length.

The Board further confirms that the transactions are not material related party transactions pursuant to Regulation 23 of SEBI Listing Regulations or the Company's Policy on Related Party Transactions.

Copies of the relevant employment records and recommendations of Nomination and Remuneration Committee, Audit Committee and Board of Directors are available for inspection by the Members at the Registered Office of the Company during business hours on any working day up to the date of the Meeting.

Mr. Ajay Bhardwaj is interested in the resolution to the extent of the remuneration payable to his relative, Mr. Ishaan Bhardwaj. Dr. Ganesh Sambasivam is interested in the resolution to the extent of the remuneration payable to his relative, Ms. Krithika Ganesh. Mr. K. Ravindra Chandrappa is interested in the resolution to the extent of the remuneration payable to his relative, Ms. Keerthana Ravindra. Except as stated above, none of the Directors, Key Managerial Personnel of

the Company or their relatives is concerned or interested, directly or indirectly financially or otherwise, in the resolution.

In accordance with Section 188 of the Companies Act, 2013 and Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the related parties shall abstain from voting on this resolution.

The Board is of the view that the continued engagement of the aforesaid employees is beneficial to the Company and that the proposed remuneration is justified having regard to their roles, responsibilities, experience and contribution to the business. Accordingly, the Board recommends the Ordinary Resolution as set out at Item No. 7 of the Notice for approval of the Members.

Item No. 8

TO APPROVE THE UPSIDE SHARING ARRANGEMENT WITH VIRIDITY TONE LLP

Pursuant to Regulation 26(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), prior approval of the Board of Directors and the public shareholders is required for any arrangement involving compensation, profit sharing or special rights, directly or indirectly, between any director, promoter, promoter group or employee of a listed entity

and any shareholder or third party in connection with dealings in the securities of such listed entity.

Viridity Tone LLP (“Investor”) invested in the Company in 2021 and held 44,564,840 equity shares of the Company as on 16 July 2025 i.e. the date of filing of the Prospectus. As part of the Offer for Sale in the initial public offering, the Investor divested 23,251,045 equity shares and subsequently divested a further 20,313,795 equity shares on March 9, 2026.

The Company, its Promoters and the Investor were the parties to a Shareholders’ Agreement dated March 1, 2021, as amended by a Waiver-cum-Amendment Agreement dated December 30, 2024 (collectively, the “SHA”). The SHA was approved by the Board of Directors at its meetings held on February 24, 2021 and December 14, 2024, respectively. From a transparency and disclosure requirement, the SHA documents have been disclosed as Material Documents in the DRHP dated December 31, 2024, RHP dated July 8, 2025 and Prospectus dated July 16, 2025 and also uploaded on the Company’s website at <https://anthebio.com/investors/>

Pursuant to the SHA, in the event the Investor sells all or any part of its shareholding at any time after listing of the Company’s shares, which results in the Investor receiving a return on its original investment, which is in excess of, the higher of (a) 25% IRR on the amount invested by the Investor, and (b) 2 times the amount invested by the Investor (such excess amount, hereinafter referred to as the “Upside”) at the time of such sale, the Investor will share with Ajay Bhardwaj, Ganesh Sambasivam and K Ravindra Chandrappa (“Upside Principal Shareholders”) an amount equal to such percentage of the Upside as may be mutually agreed between the Upside Principal Shareholders and the Investor (“Upside Share Amount”), in cash or in such manner as may be agreed in writing (other than by way of transfer of any shares of the Company), subject to applicable law (“Upside Sharing Arrangement”). Additional details on the Upside Sharing Arrangement are available at Clause 2.11 of the Waiver-cum-Amendment Agreement dated December 30, 2024.

The Upside Sharing Arrangement was negotiated and agreed, prior to the listing of the Company’s shares and was disclosed in the Prospectus under the section titled “History and Certain Corporate Matters” on page 237. The Upside Sharing Arrangement is contractual in nature and operates solely between the Investor and the Upside Principal Shareholders.

The Company is not required to make any payment under the arrangement nor bear any financial obligation nor is liable in relation thereto and does not derive any benefit from, or incur any cost on account of the said arrangement.

The Upside Sharing Arrangement does not contemplate any issuance, allotment or transfer of securities by the Company.

After the Upside Sharing Arrangement is implemented, the promoters’ economic exposure to the Company will remain substantially aligned with that of long-term shareholders in the Company, as the promoters’ cumulative holding in the Company remains at 71.63%. Importantly, there is no cash outflow or financial obligation on the Company in respect of this Upside Sharing Arrangement, and accordingly, it does not impact the Company’s operations, cash flows, or long-term profitability.

A payout under the Upside Sharing Arrangement has been triggered on account of a substantial increase in the Company’s share price, thereby benefiting all shareholders at large.

The Board of Directors, at its meeting held on April 22, 2026, reviewed the operation of the Upside Sharing Arrangement and were informed that pursuant to the aggregate net realisation of approximately INR 13,170 million by the Investor from divestments of its shareholding in the Company, the Investor and the Upside Principal Shareholders have mutually agreed that the Upside Sharing Amount payable by the Investor to the Upside Principal Shareholders in accordance with the terms of the SHA shall be approximately INR 1,276.83 million. The Board further noted that the arrangement falls within the scope of Regulation 26(6) of the SEBI Listing Regulations and, accordingly, approved and recommended the Upside Sharing Arrangement for approval of the public shareholders of the Company.

The Board is satisfied that the Upside Sharing Arrangement is pursuant to pre-existing contractual rights disclosed transparently to all investors through appropriate disclosures in the DRHP, RHP and Prospectus, does not impose any obligation on the Company and does not adversely affect the rights or interests of the public shareholders of the Company. Further, the Board is satisfied that the Upside Sharing Arrangement does not in any way promote short termism, or adversely affect the rights or interests of the other public shareholders of the Company, or result in alignment of promoter interests with a limited or controlled set of shareholders.

For the foregoing reasons, especially the fact that the promoters continue to hold 71.63% shares of the Company, the arrangement neither promotes short termism, nor does it result in alignment of promoter interests with a limited or controlled set of shareholders but rather is aligned with overall shareholder value creation.

Furthermore, the arrangement was fully and transparently disclosed in the Draft Red Herring Prospectus, Red Herring Prospectus, and Prospectus filed with SEBI, the Stock Exchanges, and the Registrar of Companies. Accordingly, there was no lack of disclosure to regulators or investors at any stage.

Mr. Ajay Bhardwaj, Chairman, Managing Director and Chief Executive Officer, Dr. Ganesh Sambasivam, Whole-time Director, and Mr. K. Ravindra Chandrappa, Whole-time Director, being beneficiaries under the arrangement, together with their relatives, may be deemed to be concerned or interested in the resolution to the extent of the benefits that may accrue to them. Save as aforesaid, none of the other Directors, Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution.

In accordance with Regulation 26(6) of the SEBI Listing Regulations, the Promoters, the Investor and all other interested parties shall abstain from voting on the resolution and the approval shall be obtained solely from the public shareholders of the Company.

The Board recommends the Ordinary Resolution set out at Item No. 8 of the Notice for approval of the Members.

ADDITIONAL INFORMATION ON DIRECTORS RECOMMENDED FOR APPOINTMENT / REAPPOINTMENT AS REQUIRED UNDER REGULATION 36 OF THE LODR REGULATIONS AND APPLICABLE SECRETARIAL STANDARDS

Particulars	Details
Name	Mr. K Ravindra Chandrappa
DIN	01580534
Date of Birth Age	November 02, 1966 59 years
Qualification	He holds a Bachelor’s degree in Chemical Engineering from Bangalore University and has more than 25 years of experience in the field of pharmaceutical and biopharmaceutical industry along with experience in managing large scale operations, driving process efficiencies and implementing global quality standards and has been associated with our Company and Neoanthem Lifesciences Private Limited. He is responsible for leading the end-to-end operations, including research and development, manufacturing, quality and regulatory compliance management
Experience (including experience in specific function areas)	<p>Infrastructure: He has been instrumental in designing and setting up all the three manufacturing units of Anthem, viz:</p> <ul style="list-style-type: none"> • Unit I (Bommasandra industrial area); • Unit II (Harohalli industrial area); • Unit III (Neoanthem @ Harohalli). • Company’s 4th manufacturing unit (30 Acres) is also being setup under his leadership <p>Advanced Technology and Manufacturing Capabilities:</p> <ul style="list-style-type: none"> • Innovation in modalities: Platforms such as RNA interference (“RNAi”), Antibody-Drug Conjugates (“ADCs”), peptides, lipids and oligonucleotides has been invested over time under his leadership. • Foray into green chemistry techniques, being one of the pioneers in India having introduced biotransformation as a manufacturing capability in 2014 and flow chemistry in 2019, was done under his watch <p>Regulatory Certifications:</p> <p>Under his leadership, Anthem has been consistently implementing cGMPs across each of manufacturing facilities, and the manufacturing facilities are regularly audited by clients and/ or inspected by regulatory authorities such as the USFDA, TGA (Australia), ANVISA (Brazil), PMDA (Japan) and Qualified Person (Europe).</p> <ul style="list-style-type: none"> • Unit I has cleared USFDA inspections 4 times (2013, 2016, 2019 and 2025) without any 483’s, without any observations • Unit II has cleared USFDA inspections twice (2023 and 2024) <p>Quality Systems:</p> <p>Committed to implement a robust quality system and as part of digital transformation from paper based system to a compliance digital system, implementation of Veeva Vault Quality for managing quality processes and SAP S4/HANA for material management has been done under his leadership</p>
Terms and condition for appointment	As per the resolution at item no. 3 of this Notice, Mr. K Ravindra Chandrappa, whose office, as director liable to retire by rotation at the ensuing AGM, being eligible, seeks reappointment.
Remuneration Details	In accordance with limits prescribe under the provisions of Section 197 read with Schedule V of the Companies Act, 2013
Date of first appointment on the Board	Mr. K Ravindra Chandrappa was appointed as an Executive Director of the Company on September 27, 2006 and was further re-designated as a Whole Time Director on June 10, 2025. Details pertaining to his appointment, remuneration, and number of meetings attended are provided in the Corporate governance report which forms part of the Annual Report.
Number of board meetings attended during FY 2025-26	10
Shareholding in the Company	43,646,849 equity shares of the Company constituting 7.77% of the paid up capital
Relationship with other Directors, Manager and Key Managerial Personnel of the Company	Not related to any Director, Manager or Key Managerial Personnel
Directorships of other Boards	Neoanthem Lifesciences Private Limited (Wholly Owned Subsidiary of the Company)

Particulars	Details
Membership / Chairmanship of Committees in other companies	NIL
Listed entities from which the Director has resigned in the past three years	NIL

INSTRUCTIONS FOR PARTICIPATING THROUGH VC:

Please follow the below steps for registration and participation.

Step 1	Access the VC portal by clicking this link: https://emeetings.kfintech.com	Internet connection: Broadband, wired or wireless (4G or 5G/LTE), with a speed of 10 Mbps or more
Step 2	Log in to join the VC session by using your DP ID and Client ID / Folio Number together with your PAN a) Members with NSDL account: 8-character DP ID followed by 8-digit Client ID (For example, if your DP ID is IN300*** and Client ID is 12*****, then your user ID is IN300***12*****). b) Members with CDSL account: 16-digit Beneficiary ID (For example, if your Beneficiary ID is 12*****), then your user ID is 12*****). c) Members with physical folio: ITL + Folio Number registered with the Company (For example, if your Folio Number is 0*****, then your user ID is ITL0*****)	Microphone and speakers: Built-in or USB plug-in or wireless Bluetooth Browser: All major browsers (Google Chrome: Version 90 or latest Microsoft Edge Chromium: Version 90 or latest Safari: Version 12 or latest) Internet Explorer: Not supported Helpline numbers: 1800 3094 001
	Note: Institutional / corporate shareholders are required to upload the Board Resolution / Authorization Letter authorizing its representatives to attend the AGM through VC.	
Step 3	Click 'Enter' to join the virtual AGM.	
Step 4	Members may post questions in the 'Ask a Question' section. This option will be available once the AGM proceedings have commenced. Further, Members will be enabled to ask questions through video conference as well.	
Step 5	Members who have not cast their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through the e-voting system during the AGM by following the 'Instructions for e-voting'.	

INSTRUCTION FOR E-VOTING

i. In compliance with the provisions of Sections 108 and 110 of the Act read with the Rules as amended and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time, the Company is providing facility to the Members to exercise voting through electronic voting system (“remote e-voting”) on the e-voting platform provided by KFintech. The Members may cast their votes remotely, using remote e-voting only on the dates mentioned hereunder. The instructions for remote e-voting forms part of this Notice.

Facility to exercise vote through remote e-voting will be available during the following period:

Commencement of Remote e-voting	End of Remote e-voting
July 19, 2026 (09.00 AM IST)	July 21, 2026 (5:00 PM IST)

- ii. The remote e-voting module shall be disabled by KFintech for voting thereafter. Once the vote on a resolution is cast by the Member, the Member shall not be allowed to change it subsequently or cast the vote again.
- iii. During the above period, Members of the Company holding shares as on July 17, 2026 i.e., cut-off date, may cast their vote by remote e-voting.
- iv. CS Pramod S M (Membership No. F7834) or in his absence CS Biswajit Ghosh (Membership No. F8750) Partners of M/s. BMP & Co. LLP, Practicing Company is appointed as the Scrutinizer for conducting the Postal Ballot only through remote e-voting process in a fair and transparent manner. The Scrutinizer’s decision on the validity of remote e-voting will be final.
- v. The process and manner of remote e-voting is explained below:
 - i. Access to Depositories e-voting system in case of individual Members holding shares in demat mode
 - II. Access to KFintech e-voting system in case of Members who are non-individual Members holding shares in demat mode

I. Access to Depositories e-voting system in case of individual Members holding shares in demat mode.

Type of Member	Login Method
Individual Members holding securities in demat mode with NSDL	<ol style="list-style-type: none"> <li data-bbox="470 315 1474 539">1. For OTP based login you can click on https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on the company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. <li data-bbox="470 562 1474 1010">2. Existing Internet-based Demat Account Statement (“IDeAS”) facility Users: <ol style="list-style-type: none"> <li data-bbox="502 607 1474 663">i. Visit the e-services website of NSDL https://eservices.nsd.com either on a personal computer or on a mobile. <li data-bbox="502 685 1474 741">ii. On the e-services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. Thereafter enter the existing user id and password. <li data-bbox="502 763 1474 887">iii. After successful authentication, Members will be able to see e-voting services under ‘Value Added Services’. Please click on “Access to e-voting” under e-voting services, after which the e-voting page will be displayed. <li data-bbox="502 909 1474 943">iv. Click on company name i.e. Anthem Biosciences Limited or ESP i.e. KFintech. <li data-bbox="502 965 1474 1010">v. Members will be re-directed to KFintech’s website for casting their vote during the remote e-voting period. <li data-bbox="470 1032 1474 1630">3. Those not registered under IDeAS: <ol style="list-style-type: none"> <li data-bbox="502 1077 1474 1111">i. Visit https://eservices.nsd.com for registering. <li data-bbox="502 1133 1474 1189">ii. Select “Register Online for IDeAS Portal” or click at https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp <li data-bbox="502 1211 1474 1245">iii. Visit the e-voting website of NSDL https://www.evoting.nsd.com. <li data-bbox="502 1267 1474 1323">iv. Once the home page of e-voting system is launched, click on the icon “Login” which is available under ‘Shareholder / Member’ section. A new screen will open. <li data-bbox="502 1346 1474 1402">v. Members will have to enter their User ID (i.e. the sixteen digit demat account number held with NSDL), password / OTP and a verification code as shown on the screen. <li data-bbox="502 1424 1474 1480">vi. After successful authentication, Members will be redirected to NSDL Depository site wherein they can see e-voting page. <li data-bbox="502 1503 1474 1559">vii. Click on company name i.e Anthem Biosciences Limited or ESP name i.e KFintech after which the Member will be redirected to ESP website for casting their vote during the remote e-voting period. <li data-bbox="502 1581 1474 1630">viii. Members can also download the NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.

NSDL Mobile App is available on



Type of Member	Login Method
Individual Members holding securities in demat mode with CDSL	<p>1. Existing user who have opted for Electronic Access to Securities Information (“Easi/ Easiest”) facility:</p> <ol style="list-style-type: none"> i. Visit https://web.cdslindia.com/myeasitoken/Home/Login or www.cdslindia.com. ii. Click on New System Myeasi. iii. Login to Myeasi option under quick login. iv. Login with the registered user ID and password. v. Members will be able to view the e-voting Menu. vi. The Menu will have links of KFintech e-voting portal and will be redirected to the e-voting page of KFintech to cast their vote without any further authentication. <p>2. User not registered for Easi/ Easiest</p> <ol style="list-style-type: none"> i. Visit https://web.cdslindia.com/myeasitoken/Registration/EasiRegistration or https://web.cdslindia.com/myeasitoken/Registration/EasiestRegistration for registering. ii. Proceed to complete registration using the DP ID, Client ID (BO ID), etc. iii. After successful registration, please follow the steps given in point no. 1 above to cast your vote. <p>3. Alternatively, by directly accessing the e-voting website of CDSL</p> <ol style="list-style-type: none"> i. Visit www.cdslindia.com. ii. Provide demat account number and PAN. iii. System will authenticate user by sending OTP on registered mobile and email as recorded in the demat Account. iv. After successful authentication, please enter the e-voting module of CDSL. Click on the e-voting link available against the name of the Company, viz. << COMPANY NAME >> or select KFin. v. Members will be re-directed to the e-voting page of KFin to cast their vote without any further authentication.
Individual Members login through their demat accounts / website of DPs	<ol style="list-style-type: none"> i. Members can also login using the login credentials of their demat account through their DPs registered with the Depositories for e-voting facility. ii. Once logged-in, Members will be able to view e-voting option. iii. Upon clicking on e-voting option, Members will be redirected to the NSDL / CDSL website after successful authentication, wherein they will be able to view the e-voting feature. iv. Click on options available against Anthem Biosciences Limited or ‘KFintech’. v. Members will be redirected to e-voting website of KFin for casting their vote during the remote e-voting period without any further authentication.

Important note: Members who are unable to retrieve User ID / Password are advised to use Forgot user ID and Forgot Password option available at respective websites.

Helpdesk for Individual Members holding securities in demat mode for any technical issues related to login through Depository i.e., NSDL and CDSL.

Login type	Helpdesk details
Securities held with NSDL	Please contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 102 0990 and 1800 22 4430
Securities held with CDSL	Please contact CDSL helpdesk by sending a request at helpdesk. evoting@cdslindia.com or contact at 022-62343625, 022-62343626, 022-62343259

II. Access to KFintech e-voting system in case of Members who are non-individual Members holding shares in demat mode.

Members whose e-mail IDs are registered with the Company / DPs, will receive an e-mail from KFintech which will include details of E-Voting Event Number (EVEN), USER ID and password and will follow the below mentioned process.

Members who have not registered their email IDs are requested to do so at the earliest. Members holding shares in can register their email ID by contacting their respective Depository Participant(s) (“DP”).

- i. Launch internet browser by typing the URL: <https://emeetings.kfintech.com>.
- ii. Enter the login credentials (i.e., User ID and password). In case of physical folio, User ID will be EVEN (E-Voting Event Number) xxxx, followed by folio number. In case of Demat account, User ID will be your DP ID and Client ID. However, if you are already registered with KFintech for e-voting, you can use your existing User ID and password for casting the vote.
- iii. After entering these details appropriately, click on “LOGIN”.
- iv. You will now reach password change Menu wherein you are required to mandatorily change your password. The new password shall comprise of minimum 8 characters with at least one upper case (A- Z), one lower case (a-z), one numeric value (0-9) and a special character (@, #, \$, etc.). The system will prompt you to change your password and update your contact details like mobile number, e-mail ID etc. on first login. You may also enter a secret question and answer of your choice to retrieve your password in case you forget it. It is strongly recommended that you do not share your password with any other person and that you take utmost care to keep your password confidential.
- v. You need to login again with the new credentials.
- vi. On successful login, the system will prompt you to select the “EVEN” i.e., ‘Anthem Biosciences Limited’ and click on “Submit”
- vii. On the voting page, enter the number of shares (which represents the number of votes) as on the Cut-off Date under “FOR/AGAINST” or alternatively, you may partially enter any number in “FOR” and partially “AGAINST” but the total number in “FOR/ AGAINST” taken together shall not exceed your total shareholding as mentioned herein above. You may also choose the option “ABSTAIN”. If the Member does not indicate either “FOR” or “AGAINST” it will be treated as “ABSTAIN” and the shares held will not be counted under either head.
- viii. Members holding multiple folios/demat accounts shall choose the voting process separately for each folio/ demat accounts.
- ix. In case you do not desire to cast your vote, it will be treated as abstained.
- x. You may then cast your vote by selecting an appropriate option and click on “Submit”.
- xi. A confirmation box will be displayed. Click “OK” to confirm else “CANCEL” to modify. Once you have voted on the resolution, you will not be allowed to modify your vote. During the voting period, Members can login any number of times till they have voted on the resolution.

General Guidelines for Members:

- i. Institutional Members (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution / Authority letter etc. with attested specimen signatures of the duly authorised signatory(ies) who are authorised to vote on their behalf. The documents should be emailed to inward.ris@kfintech.com with the subject line “Anthem Biosciences Limited AGM 2026”.
2. In case of any query and/ or assistance required, Members may refer to the Help & Frequently Asked Questions (“FAQs”) available at the download section of <https://evoting.kfintech.com> or contact KFintech at the email ID evoting@kfintech.com or call KFintech’s toll free No.: 1800 309 4001 for any further clarifications/ technical assistance that may be required.

OTHER INSTRUCTIONS

- a. In case of any query and/or grievance, in respect of voting by electronic means, Members may refer to the Help & Frequently Asked Questions (FAQs) and E-voting user manual available at the download section of <https://evoting.kfintech.com> (KFintech’s Website) or contact Mr. Suresh Babu, (Unit: Anthem Biosciences Limited) of KFintech, Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500 032 or at inward.ris@kfintech.com or evoting@kfintech.com or phone no. 040 – 6716 2222 or call toll free No. 1800-309-4001 for any further clarifications.
- b. You can also update your mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s).
- c. The voting rights of Members shall be in proportion to their shareholding in the paid-up equity share capital of the Company as on the cut-off date i.e. on Day, Month Date, Year.
- d. Any Member who has forgotten the User ID and Password, may obtain / generate / retrieve the same from KFintech in the manner as mentioned below:
 - i. If the mobile number of the Member is registered against Folio No./ DP ID Client ID, the Member may send SMS: MYEPWD E-Voting Event Number+Folio No. or DP ID Client ID to 9212993399

Example for NSDL: MYEPWD IN12345612345678

Example for CDSL: MYEPWD 1402345612345678

Example for Physical: MYEPWD XXXX1234567890
 - ii. If e-mail address or mobile number of the Member is registered against Folio No. / DP ID Client ID, then on the home page of <https://evoting.kfintech.com>, the Member may click “Forgot Password” and enter Folio No. or DP ID Client ID and PAN to generate a password.
 - iii. Members may call KFintech toll free number 1800-309-4001 for any assistance.
 - iv. Member may send an e-mail request to evoting@kfintech.com.



Anthem BioSciences Limited (Unit-I)

No 49, F1&F2 Canara Bank Road,
Hosur Rd, Electronics City Phase 1,
Bommasandra Industrial Area,
Bengaluru, Karnataka

Anthem BioSciences Limited (Unit-II)

Plot No 276-P & 277-P,
Sy No. 20, Bannikuppe Road,
Harohalli Industrial Area -Phase -II,
Kanakapura Taluk, Ramnagar District-562112,
Karnataka, India

NeoAnthem Lifesciences Private Limited (Unit-III)

Plot No 313-P, 314-P & 318 P,
Harohalli Industrial Area -Phase -II,
Kanakapura Taluk, Ramnagar District-562112, Karnataka, India

